Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).

• DOI: 10.1200/jco.2025.43.16_suppl.e17064
• Publication Date: 2025-05-28T16:31:09Z
• Authors: Patrick O'Shea; Matthew Labriola; Lauren Howard; Susan Halabi; Mark T. Fleming; Elisabeth I. Heath; Ronald Tutrone; Brian E. Lewis; Michael Sandon Hu...; Michael Roger Har...; Julie Kephart; Julia Hurrelbrink; Julia Rasmussen; Kellie Shobe; Monika Anand; Marco Reyes-Martinez; Steven R. Patierno; Jennifer A. Freedman; Andrew J. Armstrong; Daniel J. George

e17064 Background: Analyses of clinical trials data suggest thatBlack men have equal or even improved overall survival (OS) with certain treatments for mCRPC compared other races. Moreover, retrospective analysis the PROCEED registry indicated that Black who received Sip-T, an autologous cellular immunotherapy, had longer mCRPC. The Abi Race and PANTHER prospectively assessed effect ARPIs on outcomes among White patient (pt) cohorts, included pts Sip-T either prior to during study. We combined from investigate associations between OS, race. Methods: Data (N=100) (N=93) studies were retrospectively pooled this analysis. Propensity scores treatment calculated based Karnofsky performance status, race, Gleason score, Kaplan-Meier estimates without inverse propensity score weighting, generated stratified by use. This was race examine whether relationship use OS differed Results: Of 93 100 patients both studies, 123 did not receive while 70 (60 before study, 10 study). Pts a median (mOS) 44 months (95% Confidence Interval (CI) 39, NR) 36 CI 31, 48) those not. Weighted scores, mOS 72 43, NR), 38 30, NR). Among men, 39 32 29, (see Table). Conclusions: Our findings investigator-led independent sponsors provide trial support may greater than men. While our controlled factors influence it is limited potential unmeasured confounders timing Sip-T. Further, adequately powered prospective specifically evaluating in earlier settings are needed. Drug funding provided Janssen Scientific Affairs, LLC. Death counts Sipuleucel-T Men Deaths / Total N No 64 59 Yes 12 29 24 41 Unweighted CI) (29, (43, (31, (30, NR = reached, survival, confidence interval.